BRCA2 and cancer: PARP inhibitors block the efficient repair of nicks in double‐stranded DNA ultimately leading to the formation of more DSBs; in cancer cells with deficiencies in DSB repair, such as BRCA2‐negative cells, they become sensitive to rucaparib as it is synthetically lethal with unrepaired DSBs (due to BRCA2 deficiency, for example).